The diversified therapeutics developer has filed to go public in the United States a year after Pfizer contributed to its $310m series A round.

LianBio, a US-headquartered diversified drug developer backed by pharmaceutical firms BridgeBio and Pfizer, filed an initial public offering on the Nasdaq Global Market with a $100m placeholder target on Friday.

Founded in 2019, LianBio is developing nine drug candidates across five therapeutic areas including oncology and cardiorenal diseases, focusing on China and other Asian markets. It has partnerships in place with pharmaceutical groups including Bristol Myers Squibb, Tarsus Pharmaceuticals that also featured Pfizer.

LianBio had raised $310m in a…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Edison Fu

Edison Fu is a reporter and Asia liaison at Global Corporate Venturing.
Email LinkedIn